Retapamulin

Robert S. Daum; Santwana Kar; Peter Kirkpatrick

doi:10.1038/nrd2442

journal article Nov 01, 2007

Retapamulin

Robert S. Daum Santwana Kar Peter Kirkpatrick

Nature Reviews Drug Discovery Vol. 6 No. 11 pp. 865-866 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/nrd2442

Topics

No keywords indexed for this article. Browse by subject →

References

17

[1]

Cole, C. & Gazewood, J. Diagnosis and treatment of impetigo. Am. Fam. Physician 75, 859–864 (2007).

[2]

Kavanagh, F., Hervey, A. & Robbins, W. J. Antibiotic substances from Basidiomycetes: VIII. Pleurotus Multilus (Fr.) Sacc. and Pleurotus Passeckerianus Pilat. Proc. Natl Acad. Sci. USA 37, 570–574 (1951). 10.1073/pnas.37.9.570

[3]

Hunt, E. Pleuromutilin antibiotics. Drugs Future 25, 1163–1168 (2000). 10.1358/dof.2000.025.11.858699

[4]

Jones, R. N. et al. Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant Gram-positive cocci. Antimicrob. Agents Chemother. 50, 2583–2586 (2006). 10.1128/aac.01432-05

[5]

Rittenhouse, S. et al. Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrob. Agents Chemother. 50, 3882–3885 (2006). 10.1128/aac.00178-06

[6]

Food and Drug Administration. FDA labelling information [online] , (2007).

[7]

Yan, K. et al. Biochemical characterization of the interactions of the novel pleuromutilin derivative retapamulin with bacterial ribosomes. Antimicrob. Agents Chemother. 50, 3875–3881 (2006). 10.1128/aac.00184-06

[8]

Davidovich, C. et al. Induced-fit tightens pleuromutilins binding to ribosomes and remote interactions enable their selectivity. Proc. Natl Acad. Sci. USA 104, 4291–4296 (2007). 10.1073/pnas.0700041104

[9]

Kosowska-Shick K. et al. Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes. Antimicrob. Agents Chemother. 50, 765–769 (2006). 10.1128/aac.50.2.765-769.2006

[10]

Rittenhouse, S. et al. Use of the surgical wound infection model to determine the efficacious dosing regimen of retapamulin, a novel topical antibiotic. Antimicrob. Agents Chemother. 50, 3886–3888 (2006). 10.1128/aac.00183-06

[11]

European Medicines Agency. European Public Assessment Report [online] , (2007).

[12]

Daum, R. S. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N. Engl. J. Med. 357, 380–390 (2007). 10.1056/nejmcp070747

[13]

Han, L. L. et al. High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. J. Clin. Microbiol. 45, 1350–1352 (2007). 10.1128/jcm.02274-06

[14]

Diep, B. A. et al. Complete genome sequence of USA300, an epidemic clone of community-acquired methicillin-resistant Staphylococcus aureus. Lancet 367, 731–739 (2006). 10.1016/s0140-6736(06)68231-7

[15]

Gentry, D. R. et al. Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin. Antimicrob. Agents Chemother. 51, 2048–2052 (2007). 10.1128/aac.01066-06

[16]

Jones, R. N. et al. Contemporary antimicrobial activity of triple antibiotic ointment: a multiphased study of recent clinical isolates in the United States and Australia. Diagn. Microbiol. Infect. Dis. 54, 63–71 (2006). 10.1016/j.diagmicrobio.2005.08.009

[17]

IMS Health. IMS MIDAS Quantum (2006).

Metrics

70

Citations

17

References

Details